| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |